Moving Toward a Targeted Approach for Nasal Polyps
Speakers: John Bosso, MD, Clinical Profressor, Division of RhinologyZachary Soler, MD, MSc, Associate Professor of Otolaryngology Head Neck SurgerySanaz Eftekhari, Vice President of Corporate Affairs and Research
Duration: 60 minutes
Presented on: July 30, 2021
John Bosso, MD
John Bosso, MD
Clinical Profressor, Division of RhinologyJohn V. Bosso, MD, serves as medical director of the Aspirin Exacerbated Respiratory Disease (AERD or Samter’s triad) Center and director of the OTO-Allergy Clinic at Penn Medicine in Philadelphia. He is one of the country’s most experienced AERD super-specialists with over 30 years of expertise in managing this challenging condition. Dr Bosso was one of the first allergy/immunology fellows to learn the techniques of aspirin desensitization and has subsequently successfully desensitized over 1000 AERD patients. His current research focuses on potential causes, molecular mechanisms, and treatments of AERD. Dr Bosso has spoken at national otorhinolaryngology meetings and served on AERD panels. In addition, he is a proud supporter of the Samter’s Society, a support group for AERD sufferers.
Zachary Soler, MD, MSc
Zachary Soler, MD, MSc
Associate Professor of Otolaryngology Head Neck SurgeryZachary M. Soler, MD, MSc, is an associate professor in the Department of Otolaryngology-Head and Neck Surgery at the Medical University of South Carolina in Charleston. His clinical and surgical practice focuses on patients with refractory chronic rhinosinusitis. Dr Soler is the principal investigator of a multi-center NIH study that explores outcomes in patients with chronic rhinosinusitis. He has authored over 180 peer-reviewed publications related to rhinology.
Vice President of Corporate Affairs and ResearchSanaz Eftekhar, vice president of Corporate Affairs and Research at AAFA, leads tactical and strategic conversations with business partners and stakeholders across multiple industries. She has been instrumental in working with AAFA’s partners to present patient perspectives on the needs for atopic dermatitis treatments to the US Food and Drug Administration. In a greater effort to connect patients with vital clinical trials, Sanaz has been a key player in the development of AAFA’s upcoming clinical trial database. She has led AAFA’s involvement in the CIU & You campaign since its launch in 2015, co-authored several key AAFA research reports, and serves as secretary on the Board of Directors for the Global Allergy & Airways Patient Platform (GAAPP).
Moving Toward a Targeted Approach for Nasal Polyps
LEARNING OBJECTIVESAt the conclusion of this activity, participants will be able to:
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC, working in collaboration with the Asthma and Allergy Foundation of America (AAFA).
- Summarize the disease burden experienced by patients with NPs
- List the limitations of traditional interventions for NPs, including oral or nasal steroids, antibiotics, and surgery
- Explain the rationale for locally and immunologically targeted approaches to NP management
- Summarize the efficacy and safety of new and emerging therapies with new mechanisms of action and/or modes of administration for people with NPs
This activity is supported by an independent medical education grant from OptiNose US Inc, Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
JOINT ACCREDITATION STATEMENTIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
LIVE CREDIT DESIGNATION STATEMENTThe Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ENDURING CREDIT DESIGNATION STATEMENTThe Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DATE OF RELEASE/EXPIRATION
Live ActivityFriday, July 30, 2021 from 3:00 – 4:00pm ET
Enduring MaterialThe enduring material will be available from July 30, 2021 to July 30, 2022.
TARGET AUDIENCEThe intended audience for this activity are otorhinolaryngologists (ORLs), allergists, primary care physicians, advanced practitioners (nurse practitioners and physician assistants), and nurses.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 1 hour to complete.
METHOD OF PARTICIPATIONThere are no fees to participate in this activity. To participate in the activity, go to www.ImmunologyLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
DISCLOSURE OF CONFLICTS OF INTERESTPostgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship John V. Bosso, MD
Division of Rhinology
Deptartment of Otorhinolaryngology: Head and Neck Surgery
University of Pennsylvania
Perelman School of Medicine
Consulting Fees (e.g., advisory boards): GSK, Novartis, Sanofi-Regeneron, AstraZeneca
Contracted Research: OptiNose US Inc
Vice President, Corporate Affairs and Research
Asthma and Allergy Foundation of America
Nothing to disclose Zachary M. Soler, MD, MSc
Associate Professor of Otolaryngology Head Neck Surgery
Medical University of South Carolina
Consulting Fees (e.g., advisory boards): GSK, Lyra, Novartis, OptiNose US Inc, Sinusonic
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship Carole Drexel
PlatformQ Health Education, LLC
The PIM planners and managers have nothing to disclose.
The following PlatformQ Health Education, LLC planner, Jaimee Harris-Gold, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT INFORMATIONAccreditation Support: Please contact the Postgraduate Institute for Medicine at www.pimed.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@ImmunologyLive.com.